PURPOSE: The purpose of this study is to study the influence of radical prostatectomy (RP) for prostate cancer on work status and working life in men 3 years after surgery. METHODS: In a prospective, questionnaire-based study on adverse effects after RP, 330 prostate cancer (PCa) patients who had been active in the workforce before RP described their work status 3 years after having surgery. We dichotomized their postoperative work status into "unchanged or increased" versus "reduced." The participants also reported whether their working life was influenced by the PCa trajectory to no, some, or a great extent. Univariate and multiple logistic regression models were established with sociodemographic and clinical characteristics as independent variables and "work status" or "influence of PCa trajectory on working life" as dependent variables. RESULTS: Twenty-five percent of the participants had retired. Of the remaining participants, approximately 20 % had a reduced work status, which in the multivariate analyses was significantly associated with increasing age. One third of the men still active in the workforce considered the PCa to negatively influence their working life. This was independently associated with bother related to urinary leakage, fatigue, and having undergone additional oncological therapy (pelvic radiotherapy and/or hormone treatment). CONCLUSION: Though RP does not affect work status in most men, approximately one third of them experience problems in their working life due to adverse effects related to RP and/or additional post-RP anti-cancer therapy. IMPLICATIONS FOR CANCER SURVIVORS: Most PCa survivors can expect to remain in the workforce for at least 3 years after RP, but for some, persistent adverse effects after RP and /or additional anti-cancer treatment negatively affect their working life. Pre-RP counseling of men within the workforce should cover possible post-RP changes concerning work status and working life.
PURPOSE: The purpose of this study is to study the influence of radical prostatectomy (RP) for prostate cancer on work status and working life in men 3 years after surgery. METHODS: In a prospective, questionnaire-based study on adverse effects after RP, 330 prostate cancer (PCa) patients who had been active in the workforce before RP described their work status 3 years after having surgery. We dichotomized their postoperative work status into "unchanged or increased" versus "reduced." The participants also reported whether their working life was influenced by the PCa trajectory to no, some, or a great extent. Univariate and multiple logistic regression models were established with sociodemographic and clinical characteristics as independent variables and "work status" or "influence of PCa trajectory on working life" as dependent variables. RESULTS: Twenty-five percent of the participants had retired. Of the remaining participants, approximately 20 % had a reduced work status, which in the multivariate analyses was significantly associated with increasing age. One third of the men still active in the workforce considered the PCa to negatively influence their working life. This was independently associated with bother related to urinary leakage, fatigue, and having undergone additional oncological therapy (pelvic radiotherapy and/or hormone treatment). CONCLUSION: Though RP does not affect work status in most men, approximately one third of them experience problems in their working life due to adverse effects related to RP and/or additional post-RP anti-cancer therapy. IMPLICATIONS FOR CANCER SURVIVORS: Most PCa survivors can expect to remain in the workforce for at least 3 years after RP, but for some, persistent adverse effects after RP and /or additional anti-cancer treatment negatively affect their working life. Pre-RP counseling of men within the workforce should cover possible post-RP changes concerning work status and working life.
Authors: Elizabeth A Grunfeld; Lawrence Drudge-Coates; Lorna Rixon; Emma Eaton; Alethea F Cooper Journal: Health Psychol Date: 2013-01 Impact factor: 4.267
Authors: Kathleen Oberst; Cathy J Bradley; Joseph C Gardiner; Maryjean Schenk; Charles W Given Journal: J Cancer Surviv Date: 2010-06-12 Impact factor: 4.442
Authors: Sigrun Dahl; Eivind A S Steinsvik; Alv A Dahl; Jon Håvard Loge; Milada Cvancarova; Sophie D Fosså Journal: Acta Oncol Date: 2013-11-06 Impact factor: 4.089
Authors: Matthew J Resnick; Daniel A Barocas; Alicia K Morgans; Sharon E Phillips; Vivien W Chen; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Karen E Hoffman; Sherri H Kaplan; Lisa E Paddock; Antoinette M Stroup; Xiao-Cheng Wu; Tatsuki Koyama; David F Penson Journal: Cancer Date: 2014-02-07 Impact factor: 6.860
Authors: Sean F Mungovan; Jaspreet S Sandhu; Oguz Akin; Neil A Smart; Petra L Graham; Manish I Patel Journal: Eur Urol Date: 2016-07-06 Impact factor: 20.096
Authors: Erin K Tagai; Shawna V Hudson; Michael A Diefenbach; Jenny Xu; Alicja Bator; Allison Marziliano; Suzanne M Miller Journal: J Cancer Surviv Date: 2020-07-18 Impact factor: 4.442